

Horizon Blue Cross Blue Shield of New Jersey Medical Injectables Program

Injectable Medications subject to Medical Necessity and Appropriateness Review (MNAR)

The injectable medications on the following pages are subject to MNAR as part of the Horizon BCBSNJ Medical Injectables Program (MIP). This injectable medication list is organized alphabetically by generic name within the following therapeutic categories.

Therapeutic Categories	see page
Amyotrophic Lateral Sclerosis	1
Anemia	1
Anemia (Dialysis)	1
Anti-emetics	1
Asthma	1
Auto-inflammatory Conditions.....	1
Chemotherapy Protectant	2
Endocrine Disorders.....	2
Enzyme Deficiency.....	2
Hematological Conditions	3
Hemophilia ¹	3
Hereditary Angioedema	4
HIV/AIDS	4
Immunodeficiency	4
Inflammatory Conditions	4
Macular Degeneration	4
Metabolic Conditions.....	5
Multiple Sclerosis	5
Musculoskeletal Conditions	5
Neutropenia.....	5
Oncology	5
Osteoarthritis.....	7
Osteoporosis	7
Spinal muscular atrophy.....	7
Thrombocytopenia	7

¹ Beginning for services to be provided on and after August 15, 2019, Magellan Rx Management will conduct medical necessity and appropriateness review for the listed hemophilia drugs.

This document was last revised on June 28, 2019, and may be subject to change.

This document contains prescription brand name drugs that are registered marks or trademarks of pharmaceutical manufacturers that are not affiliated with either Horizon Blue Cross Blue Shield of New Jersey or the Blue Cross and Blue Shield Association.



Amyotrophic Lateral Sclerosis

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Radicava	edaravone	J1301	2/1/2019

Anemia

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Aranesp	darbepoetin alfa	J0881	
Procrit/Epogen	epoetin alfa	J0885	
Retacrit (non-ESRD)	epoetin alfa-epbx biosimilar (non-ESRD)	Q5106	
Mircera (non-ESRD)	methoxy polyethylene glycol-epoetin beta (non-ESRD)	J0888	

Anemia (Dialysis)

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Aranesp (ESRD Only)	darbepoetin alfa (ESRD Only)	J0882	
Procrit/Epogen (ESRD Only)	epoetin alfa (ESRD Only)	Q4081	
Retacrit (ESRD Only)	epoetin alfa-epbx biosimilar (ESRD Only)	Q5105	
Mircera (ESRD Only)	methoxy polyethylene glycol-epoetin beta (ESRD Only)	J0887	

Anti-emetics

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Cinvanti	aprepitant	J0185	2/1/2019
Akynzeo IV	fosnetupitant/palonosetron	J1454	2/1/2019
Sustol	granisetron extended-release	J1627	
Aloxi	palonosetron	J2469	
Varubi	rolapitant	J2797	2/1/2019

Asthma

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Fasenra	benralizumab	J0517	2/1/2019
Nucala	mepolizumab	J2182	
Xolair	omalizumab	J2357	
Cinqair	reslizumab	J2786	

Auto-inflammatory Conditions

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Orencia IV	abatacept	J0129	
Benlysta IV	belimumab	J0490	
Cimzia	certolizumab pegol	J0717	
Simponi_Aria	golimumab	J1602	
Remicade	infliximab	J1745	

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.

Auto-inflammatory Conditions (*continued*)

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Renflexis	infliximab-abda	Q5104	
Inflectra	infliximab-dyyb	Q5103	
Ilumya	tildrakizumab-asmn	J3245	2/1/2019
Actemra IV	tocilizumab	J3262	
Stelara	ustekinumab	J3357	
Stelara IV	ustekinumab	J3358	
Entyvio	vedolizumab	J3380	

Chemotherapy Protectant

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Fusilev	levoleucovorin calcium	J0641	

Endocrine Disorders

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
H. P. Acthar	corticotropin	J0800	
Somatuline Depot	lanreotide	J1930	3/18/2019
Sandostatin LAR	octreotide	J2353	
Signifor LAR	pasireotide long acting	J2502	3/18/2019

Enzyme Deficiency

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Fabrazyme	agalsidase beta	J0180	
Lumizyme	alglucosidase alfa	J0221	
Aralast NP	alpha-1-proteinase inhibitor	J0256	3/18/2019
Glassia	alpha-1-proteinase inhibitor	J0257	3/18/2019
Prolastin-C	alpha-1-proteinase inhibitor	J0256	3/18/2019
Zemaira	alpha-1-proteinase inhibitor	J0256	3/18/2019
Brineura	cerliponase alfa	J0567	2/1/2019
Vimizim	elosulfase alfa	J1322	
Naglazyme	galsulfase	J1458	
Elaprased	idursulfase	J1743	
Cerezyme	imiglucerase	J1786	
Aldurazyme	laronidase	J1931	
Kanuma	sebelipase alfa	J2840	
Elelyso	taliglucerase alfa	J3060	
Vpriv	velaglucerase alfa	J3385	
Mepsevii	vestronidase alfa-vjbc	J3397	2/1/2019

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.

Hematological Conditions

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Soliris	eculizumab	J1300	

Hemophilia

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Recombinate	antihemophilic factor (recombinant)	J7192	8/15/2019
Kovaltry	antihemophilic factor (recombinant)	J7211	8/15/2019
Koate-Dvi	antihemophilic factor (human)	J7190	8/15/2019
Monoclate-P	antihemophilic factor (human)	J7190	8/15/2019
Advate	antihemophilic factor (recombinant)	J7192	8/15/2019
Helixate Fs	antihemophilic factor (recombinant)	J7192	8/15/2019
Kogenate	antihemophilic factor (recombinant)	J7192	8/15/2019
Novoeight	antihemophilic factor (recombinant)	J7182	8/15/2019
Nuwiq	antihemophilic factor (recombinant)	J7209	8/15/2019
Xyntha	antihemophilic factor (recombinant)	J7185	8/15/2019
Adynovate	antihemophilic factor (recombinant), pegylated	J7207	8/15/2019
Jivi	antihemophilic factor (recombinant), pegylated-aucl	J7208	8/15/2019
Obizur	antihemophilic factor (recombinant), porcine sequence	J7188	8/15/2019
Afstyla	antihemophilic factor (recombinant), single chain	J7210	8/15/2019
Alphanate	antihemophilic factor/von willebrand factor complex (human)	J7186	8/15/2019
Humate-P	antihemophilic factor/von willebrand factor complex (human)	J7187	8/15/2019
Hemofil M	antihemophilic factor (human)	J7190	8/15/2019
Eloctate	antihemophilic factor (recombinant), fc fusion protein	J7205	8/15/2019
Feiba Nf	anti-inhibitor coagulation complex	J7198	8/15/2019
Feiba Vf	anti-inhibitor coagulation complex	J7198	8/15/2019
Alphanine Sd	coagulation factor IX (Human)	J7193	8/15/2019
Mononine	coagulation factor IX (human)	J7193	8/15/2019
Ixinity	coagulation factor IX (recombinant)	J7195	8/15/2019
Rixubis	coagulation factor IX (recombinant)	J7200	8/15/2019
Idelvion	coagulation factor IX (recombinant), albumin fusion protein	J7202	8/15/2019
Alprolix	coagulation factor IX (recombinant), fc fusion protein	J7201	8/15/2019
Rebinyn	coagulation factor IX (recombinant), glycopegylated	J7203	8/15/2019
Novoseven Rt	coagulation factor VIIa (recombinant)	J7189	8/15/2019
Coagadex	coagulation factor X (human)	J7175	8/15/2019
Tretten	coagulation factor XIII a-subunit (recombinant)	J7181	8/15/2019
Benefix	coagulation factor IX (recombinant)	J7195	8/15/2019
Hemlibra	emicizumab-kxwh	J7170	8/15/2019
Bebulin	factor IX complex	J7194	8/15/2019
Profilnine S/D	factor IX complex	J7194	8/15/2019
Corifact	factor VIII concentrate (human)	J7180	8/15/2019

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.

Hemophilia (*continued*)

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Vonvendi	von willebrand factor (recombinant)	J7179	8/15/2019
Wilate	von willebrand factor/coagulation factor VIII compelx	J7183	8/15/2019

Hereditary Angioedema

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Ruconest	c1 esterase inhibitor [recombinant]	J0596	
Berinerit	c1 inhibitor (human)	J0597	
Cinryze	c1 inhibitor (human)	J0598	
Kalbitor	ecallantide	J1290	

HIV/AIDS

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Trogarzo	ibalizumab-uiyk	J1746	2/1/2019

Immunodeficiency

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Bivigam	IV immune globulin	J1556	
Carimune NF	IV immune globulin	J1566	
Flebogamma, Flebogamma DIF	IV immune globulin	J1572	
Gammagard Liquid	IV immune globulin	J1569	
Gammaplex	IV immune globulin	J1557	
Gamunex-C, Gammaked	IV immune globulin	J1561	
Unclassified IV Immune Globulin	IV immune globulin	J1599	
Octagam	IV immune globulin	J1568	
Privigen	IV immune globulin	J1459	
Cuvitru	subcutaneous immune globulin	J1555	
Hizentra	subcutaneous immune globulin	J1559	
Hyqvia	subcutaneous immune globulin	J1575	

Inflammatory Conditions

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Krystexxa	pegloticase	J2507	

Macular Degeneration

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Eylea	aflibercept	J0178	
Macugen	pegaptanib sodium	J2503	
Lucentis	ranibizumab	J2778	

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.

Metabolic Conditions

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Crysvita	burosumab-twza	J0584	2/1/2019

Multiple Sclerosis

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Lemtrada	alemtuzumab	J0202	
Tysabri	natalizumab	J2323	
Ocrevus	ocrelizumab	J2350	

Musculoskeletal Conditions

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Dysport	abobotulinumtoxina	J0586	
Xeomin	incobotulinumtoxina	J0588	
Botox	onabotulinumtoxina	J0585	
Myobloc	rimabotulinumtoxinb	J0587	

Neutropenia

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Neupogen	filgrastim	J1442	
Nivestym	filgrastim-aafi	Q5110	2/1/2019
Zarxio	filgrastim-sndz	Q5101	
Neulasta	pegfilgrastim	J2505	
Fulphila	pegfilgrastim-jmbd	Q5108	2/1/2019
Udenyca	pegfilgrastim-cbqv	Q5111	2/1/2019
Leukine	sargramostim	J2820	
Granix	tbo-filgrastim	J1447	

Oncology

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Kadcyla	ado-trastuzumab emtansine	J9354	
Erwinaze	asparaginase	J9019	
Tecentriq	atezolizumab	J9022	
Bavencio	avelumab	J9023	
Beleodaq	belinostat	J9032	
Bendeka	bendamustine	J9034	
Treanda	bendamustine	J9033	
Belrapzo	bendamustine hydrochloride	J9036	8/1/2019
Avastin (Cancer Dxs Only)	bevacizumab (cancer dxs only)	J9035	
Mvasi	bevacizumab-awwb	Q5107	

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.

Oncology (continued)

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Blincyto	blinatumomab	J9039	
Bortezomib	bortezomib	J9044	2/1/2019
Velcade	bortezomib	J9041	
Adcetris	brentuximab vedotin	J9042	
Jevtana	cabazitaxel	J9043	
Kyprolis	carfilzomib	J9047	
Erbix	cetuximab	J9055	
Aliqopa	copanlisib	J9057	2/1/2019
Darzalex	daratumumab	J9145	
Vyxeos	daunorubicin; cytarabine liposomal	J9153	2/1/2019
Imfinzi	durvalumab	J9173	2/1/2019
Empliciti	elotuzumab	J9176	
Halaven	eribulin	J9179	
Mylotarg	gemtuzumab ozogamicin	J9203	
Besponsa	inotuzumab ozogamicin	J9229	2/1/2019
Yervoy	ipilimumab	J9228	
Onivyde	irinotecan liposome	J9205	
Portrazza	necitumumab	J9295	
Opdivo	nivolumab	J9299	
Gazyva	obinutuzumab	J9301	
Arzerra	ofatumumab	J9302	
Lartruvo	olaratumab	J9285	
Synribo	omacetaxine	J9262	
Abraxane	paclitaxel protein-bound	J9264	
Vectibix	panitumumab	J9303	
Oncaspar	pegaspargase	J9266	
Keytruda	pembrolizumab	J9271	
Alimta	pemetrexed	J9305	
Perjeta	pertuzumab	J9306	
Mozobil	plerixafor	J2562	
Cyramza	ramucirumab	J9308	
Rituxan	rituximab	J9312	
Truxima	rituximab-abbs	Q5115	8/1/2019
Rituxan Hycela	rituximab/hyaluronidase	J9311	
Sylvant	siltuximab	J2860	
Provenge	sipuleucel-T	Q2043	
Imlygic	talimogene laherparepvec	J9325	
Yondelis	trabectedin	J9352	
Perjeta	pertuzumab	J9306	

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.

Oncology (*continued*)

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Herceptin	trastuzumab	J9355	
Ogiviri	trastuzumab-dkst	Q5114	8/1/2019
Ontruzant	trastuzumab-dttb	Q5112	8/1/2019
Herceptin Hylecta	trastuzumab-hyaluronidase-oysk	J9356	8/1/2019
Herzuma	trastuzumab-pkrb	Q5113	8/1/2019
Marqibo	vincristine liposomal	J9371	
Zaltrap	ziv-aflibercept	J9400	

Osteoarthritis

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Durolane	hyaluronan or derivative	J7318	2/1/2019
Gel-One	hyaluronan or derivative	J7326	
Gelsyn-3	hyaluronan or derivative	J7328	
Genvisc 850	hyaluronan or derivative	J7320	
Hyalgan	hyaluronan or derivative	J7321	
Hymovis	hyaluronan or derivative	J7322	
Supartz	hyaluronan or derivative	J7321	
TriVisc	hyaluronan or derivative	J7329	2/1/2019
Visco-3	hyaluronan or derivative	J7321	

Osteoporosis

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Prolia, Xgeva	denosumab	J0897	

Spinal muscular atrophy

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Spinraza	nusinersen	J2326	

Thrombocytopenia

Medication Brand Name	Generic Medication Name	HCPCS Code	Effective Date ²
Nplate	romiplostim	J2796	

² The Effective Date field displays information only for those drugs that have been recently added as part of this program or for drugs that will be added to this program in the near future.